Last reviewed · How we verify

NCT04074486: BSC-CI-NPC

Evaluation and Validation of a Multimodal Brain Function Biomarker With NPC

Completed Last updated 10 June 2022
What this trial tests

trial testing BrainScope Ahead 300iP-O in Brain Injuries in 1,318 participants. Completed in 31 March 2022.

Timeline
2 October 2019
Primary endpoint
31 January 2022
31 March 2022

Quick facts

Lead sponsorBrainScope Company, Inc.
StatusCompleted
Study typeOBSERVATIONAL
Enrollment1,318
Start date2 October 2019
Primary completion31 January 2022
Estimated completion31 March 2022
Sites6 locations across United States

Drugs / interventions tested

Conditions studied

Sponsor

BrainScope Company, Inc.

Who can join

Adults 13 to 50, any sex, with Brain Injuries or Concussion, Mild. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is designed to collect data which will be used to associate changes in EEG, neurocognitive performance, eNPC and clinical symptoms in concussion subtypes. The study will recruit males and females, 13-50 years old, from Concussion Centers/Programs, Sports Venues and Emergency Departments (ED) across the country, over an 18-month period (Phase 2, 12 months for Algorithm Development and Norming, and Phase 3, 6 months for Validation).

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Brain Injuries

Currently open trials in the same condition.

Other BrainScope Company, Inc. trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04074486.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing